Then, using a comparison of KRAS mutations between the high-risk group and the low-risk group, we identified a total of 15 highly effective drugs in the two chemical databases, among which dacomitinib, pelitinib, dacomitinib, and pelitinib are EGFR pathway inhibitors whose effects on pancreatic cancer cells have been previously reported (28). Here, KRAS is linked to familial pancreatic carcinoma.